Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

272
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
272
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

510
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
510
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

537
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
537
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

1.8K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenogroup-based stratification of cardiovascular risk in obstructive sleep apnea.

American journal of preventive cardiology·2026
Same author

Portopulmonary hypertension and serum endothelin-1 levels in patients with liver cirrhosis.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2026
Same author

Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial.

JAMA·2026
Same author

From Failure to Promise: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition in Atherosclerotic Cardiovascular Disease.

Journal of the American Heart Association·2026
Same author

Combined effect of educational attainment and diabetes on 1-year all-cause mortality in heart failure patients: findings from the National Heart Failure Registry, India.

Open heart·2026
Same author

Financial Burden, Out-of-Pocket Health Spending, and Household Economic Well-Being in Heart Failure Patients in India: A Multicentre Cross-Sectional Survey.

Global heart·2026

Related Experiment Video

Updated: Dec 27, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Triglycerides and Cardiovascular Outcomes-Can We REDUCE-IT ?

Akshyaya Pradhan1, Monika Bhandari1, Pravesh Vishwakarma1

  • 1Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India.

The International Journal of Angiology : Official Publication of the International College of Angiology, Inc
|March 6, 2020
PubMed
Summary

High-dose omega-3 fatty acids show promise in reducing cardiovascular events, especially in patients with elevated triglycerides despite statin therapy. Further research confirms their potential role in managing residual cardiovascular risk.

Keywords:
cardiovascular diseaseomega-3 fatty acidsstatinstriglycerides

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.6K

Related Experiment Videos

Last Updated: Dec 27, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.6K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipid Metabolism

Background:

  • The relationship between triglycerides and coronary artery disease (CAD) remains debated.
  • Triglyceride-lowering therapies, including fibrates, often show limited benefits for cardiovascular risk reduction when added to statins.
  • A significant residual cardiovascular risk persists even with optimal low-density lipoprotein (LDL) cholesterol management.

Purpose of the Study:

  • To evaluate the efficacy of high-dose omega-3 fatty acids in mitigating cardiovascular events.
  • To assess the role of omega-3 fatty acids in managing residual cardiovascular risk in patients with hypertriglyceridemia.
  • To clarify the controversial link between triglyceride levels and cardiovascular outcomes.

Main Methods:

  • Review of recent large-scale clinical trials investigating high-dose omega-3 fatty acid supplementation.
  • Analysis of cardiovascular outcomes in patient cohorts receiving omega-3s alongside LDL-lowering therapies.
  • Examination of studies focusing on the triglyceride-lowering effects of omega-3 fatty acids.

Main Results:

  • While older trials yielded mixed results, recent large trials with high-dose omega-3 fatty acids demonstrate promising cardiovascular benefits.
  • Omega-3 fatty acids effectively reduce triglyceride levels.
  • These benefits appear to be additive to the effects of statin therapy, addressing residual risk.

Conclusions:

  • High-dose omega-3 fatty acids represent a potential therapeutic option for reducing cardiovascular events, particularly in patients with elevated triglycerides.
  • They offer a strategy to manage residual cardiovascular risk that persists despite effective LDL cholesterol reduction.
  • Further investigation into specific formulations and patient populations is warranted.